Literature DB >> 21061193

Duration of chemotherapy for early stage breast cancer: have we reached the limit? What is the survival impact of amenorrhea?

Rebecca L Hirsh, Kevin R Fox.   

Abstract

Entities:  

Year:  2010        PMID： 21061193     DOI： 10.1007/s11864-010-0123-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN： 1534-6277


× No keyword cloud information.
  5 in total

1.  Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).

Authors:  Nancy E Davidson; Anne M O'Neill; Allen M Vukov; C Kent Osborne; Silvana Martino; Douglas R White; Martin D Abeloff
Journal:  J Clin Oncol       Date:  2005-08-08       Impact factor: 44.544

2.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.

Authors:  B Fisher; A M Brown; N V Dimitrov; R Poisson; C Redmond; R G Margolese; D Bowman; N Wolmark; D L Wickerham; C G Kardinal
Journal:  J Clin Oncol       Date:  1990-09       Impact factor: 44.544

3.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.

Authors:  W C Wood; D R Budman; A H Korzun; M R Cooper; J Younger; R D Hart; A Moore; J A Ellerton; L Norton; C R Ferree
Journal:  N Engl J Med       Date:  1994-05-05       Impact factor: 91.245

4.  Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.

Authors:  J Cuzick; L Ambroisine; N Davidson; R Jakesz; M Kaufmann; M Regan; R Sainsbury
Journal:  Lancet       Date:  2007-05-19       Impact factor: 79.321

5.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.